-transparent.png){kind=logo}
Development of a circulating inhibitor of the coagulant activity of factor VIII is a rare event producing a clinical picture similar to that of classic hemophilia. A case of autoimmune factor VIII inhibitor has been presented. Although a hemostatic response was rapidly achieved with the infusion of factor IX concentrates, immunosuppressive therapy was initiated. The inhibitor disappeared in less than 20 days from the initiation of therapy.
Related Publications
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
November 2009,
Anesthesiology,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
January 2015,
Medicina,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
September 2004,
The American surgeon,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
January 1993,
Annales de dermatologie et de venereologie,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
July 2010,
Arthritis care & research,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
October 1995,
Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
March 1983,
The West Virginia medical journal,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
April 2018,
Journal of cardiothoracic and vascular anesthesia,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
May 1989,
Annals of internal medicine,
W G Simpson, and
J Neefe, and
J Zang, and
R Drosick, and
R Kearns
April 1976,
Ugeskrift for laeger,
